IthaID: 2867



Names and Sequences

Functionality: Disease modifying mutation Pathogenicity: N/A
Common Name: rs8175347 HGVS Name: NG_002601.2:g.175492_175493TA[5][6][7][8]

Context nucleotide sequence:
TTGGTGTATCGATTGGTTTTTGCCA [(TA)5/6/7/8] AGTAGGAGAGGGCGAACCTCTGGCA (Strand: +)

Also known as:

Comments: SNP associated with risk of cholelithiasis and variation in bilirubin levels in the Cooperative Study of Sickle Cell Disease (CSSCD; n=276), in the BABY HUG cohort (n=190), in individuals from Portugal with African descend (n=153), and in sickle cell disease (SCD) cohorts from France (n=158), Guadeloupe (n=324), Jamaica (n=209), Tunisia (n=102) and Saudi Arabia (n=223). The co-inheritance of alpha thalassemia was shown to lower the risk of gallstones in the Saudi cohort. Also, the TA7/TA7 genotype associated with hyperbilirubinemia in patients with SCD from Southern Brazil (n=72). It has shown high prevalence in SCD patients from French Guiana. The UGT1A1 (TA)6/(TA)8 heterozygote showed positive associations with HbA2, HbF, and Hb levels, PCV values, and RBC counts in a sickle cell disease cohort from Jamaica (n=371). The UGT1A1*28 variant allele (also known as the (TA)7 allele) is characterized by the presence of seven thymine-adenine (TA) repeats in the TATA sequence of the UGT1A1 promoter, as opposed to six that characterize the wild-type allele, and leads to reduced gene expression and enzyme levels. This SNP overlaps the UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9 and UGT1A10 genes within the UGT1A locus.

We follow the HGVS sequence variant nomenclature and IUPAC standards.

External Links

Phenotype

Allele Phenotype (Cis):Decreased expression for UGT1A1
Allele Phenotype (Trans):N/A
Associated Phenotypes: Hb F levels [HP:0011904] [OMIM:141749]
Gallstones [HP:0001081] [OMIM:600803]
Bilirubin levels
Abnormal red blood cell count [HP:0020058]
Anaemia [HP:0001903]

Location

Chromosome: 2
Locus: NG_002601.2
Locus Location: 175492
Size: 2 bp
Located at: UGT1A1
Specific Location: Promoter 0

Other details

Type of Mutation: Point-Mutation(Insertion)
Effect on Gene/Protein Function: N/A
Ethnic Origin: African American, Guadeloupean, Jamaican, Portuguese, Guianese, Tunisian, Saudi, French, Brazilian
Molecular mechanism: N/A
Inheritance: Quantitative trait
DNA Sequence Determined: Yes

In silico pathogenicity prediction

Sequence Viewer

Note: The NCBI Sequence Viewer is not installed on the ITHANET servers but it is embedded in this page from the NCBI. Therefore, IthaGenes has no responsibility over any temporary unavailability of the service. In such a case, please Refresh the page or retry at a later stage. Otherwise, use this external link.

Publications / Origin

  1. Chaar V, Kéclard L, Diara JP, Leturdu C, Elion J, Krishnamoorthy R, Clayton J, Romana M, Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia., Haematologica , 90(2), 188-99, 2005 PubMed
  2. Haverfield EV, McKenzie CA, Forrester T, Bouzekri N, Harding R, Serjeant G, Walker T, Peto TE, Ward R, Weatherall DJ, UGT1A1 variation and gallstone formation in sickle cell disease., Blood , 105(3), 968-72, 2005 PubMed
  3. Carpenter SL, Lieff S, Howard TA, Eggleston B, Ware RE, UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia., Am. J. Hematol. , 83(10), 800-3, 2008 PubMed
  4. Martins R, Morais A, Dias A, Soares I, Rolão C, Ducla-Soares JL, Braga L, Seixas T, Nunes B, Olim G, Romão L, Lavinha J, Faustino P, Early modification of sickle cell disease clinical course by UDP-glucuronosyltransferase 1A1 gene promoter polymorphism., J. Hum. Genet. , 53(6), 524-8, 2008 PubMed
  5. Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE, , Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes., Am. J. Hematol. , 88(7), 571-6, 2013 PubMed
  6. Chaouch L, Talbi E, Moumni I, Ben Chaabene A, Kalai M, Chaouachi D, Mallouli F, Ghanem A, Abbes S, Early complication in Sickle Cell Anemia children due to A(TA)_n TAA polymorphism at the promoter of UGT1A1 gene., Dis. Markers , 2013 PubMed
  7. Chaouch L, Talbi E, Moumni I, Ben Chaabene A, Kalai M, Chaouachi D, Mallouli F, Ghanem A, Abbes S, Early complication in sickle cell anemia children due to A(TA)nTAA polymorphism at the promoter of UGT1A1 gene., Dis. Markers , 35(2), 67-72, 2013 PubMed
  8. Hamad Z, Aljedai A, Halwani R, AlSultan A, UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease., Ann Saudi Med , 33(4), 372-6, 2013 PubMed
  9. Christine S, Narcisse E, Philippe J, Tania V, Mathieu N, Genetic modulators of sickle cell disease in French Guiana: Markers of the slave trade., Am. J. Hum. Biol. , 2016 PubMed
  10. Joly P, Renoux C, Lacan P, Bertrand Y, Cannas G, Garnier N, Cuzzubbo D, Kebaïli K, Renard C, Gauthier A, Pialoux V, Martin C, Romana M, Connes P, UGT1A1 (TA)n genotype is not the major risk factor of cholelithiasis in sickle cell disease children., Eur. J. Haematol. , 98(3), 296-301, 2017 PubMed
  11. de Azevedo LA, Bonazzoni J, Wagner SC, Farias MG, Bittar CM, Daudt L, de Castro SM, Do Alpha Thalassemia, Fetal Hemoglobin, and the UGT1A1 Polymorphism have an Influence on Serum Bilirubin Levels and Cholelithiasis in Patients with Sickle Cell Disease?, Mol Diagn Ther , 2017 PubMed
  12. Howell S, Marshall K, Reid M, McFarlane-Anderson N, McKenzie C, A cross-sectional clinic-based study exploring whether variants within the glutathione S-transferase, haptoglobin and uridine 5'-diphospho-glucuronosyltransferase 1A1 genes are associated with interindividual phenotypic variation in sickle cell anaemia in Jamaica., Eur. J. Haematol. , 2017 PubMed
Created on 2016-05-18 16:40:56, Last reviewed on 2019-12-23 14:44:49 (Show full history)

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaGenes are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.